The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Immuron (IMC) will deprioritise its SARS-COV-2 research to focus on the clinical development of its therapeutic drug candidates
  • Immuron entered the new financial year with a newly appointed CEO at its helm, who has been working to complete an assessment of its entire product portfolio
  • Following research, the company has determined that the rapid evolution of COVID and changing treatment landscape presents significant challenges to conduct a clinical trial of COVID-19 with IMM-124E
  • As such, the company has been pursuing the antiviral activities of IMM-124E
  • Immuron is steady, trading at 9.4 cents at 1:15 pm AEST

Immuron (IMC) has deprioritised SARS-COV-2 research to focus on the clinical development of its therapeutic drug candidates.

Immuron entered the new financial year with a newly appointed CEO at its helm, who has been working to complete an assessment of the entire product portfolio, target markets and key growth drivers.

Following its research, the company said the rapid evolution of COVID and the changing treatment landscape present significant challenges to conduct a clinical trial for COVID-19 with IMM-124E.

As such, the company has been pursuing the antiviral activities of IMM-124E, working to establish a better understanding of the mechanism of action associated with the neutralising activity of the drug against COVID.

Immuron reported it has dedicated significant resources to interrogate the mechanism of SARS-CoV-2 protection, however, the mechanism of how IMM-124E provides protection against viral infection remains unclear.

Immuron was steady, trading at 9.4 cents at 1:15 pm AEST.

IMC by the numbers
More From The Market Online

Saturn yields 88% gold recoveries without milling at WA’s Apollo Hill

Saturn Metals Ltd has completed metallurgical test work on ore from its Apollo Hill project, showing…

Infini flags evidence of uranium on-site Portland Creek project to wrap up maiden run

Infini has announced it's logged evidence of uranium mineralisation at Portland Creek to wrap up the…

Bailador invests in Updoc digital healthcare platform

Bailador Technology Investments (ASX:BTI) has announced a $20million investment in Venture Startups International (Updoc).
The Market Online Video

Market Open: Australian stocks to edge up following Europe’s rates cut hopes

Australian stocks are set to rise slightly on Tuesday, following the trend in Europe as US…